Allergy
Therapeutics
plc
("Allergy Therapeutics" or the "Company")
Issue of 13
Ordinary Shares
Purchase and Cancellation of
Deferred Shares
Total Voting
Rights
PDMR
Dealing
22
January 2025 - Allergy Therapeutics
plc (AIM: AGY), the fully integrated commercial biotechnology
company specialising in allergy vaccines, announces that 13
ordinary shares of 0.1 pence each (the "Ordinary Shares", such Ordinary Shares
being the "New Shares")
were issued at an aggregate consideration of £1.001 for the purpose
of financing the purchase of 9,848,333 deferred shares of 0.1 pence
each (the "Deferred
Shares") yesterday. Each of Dr. Shaun Furlong, Chief
Financial Officer of the Company, and Karley Cheesman, company
secretary of the Company, has subscribed for 7 New Shares and 6 New
Shares, respectively. Subsequent to the issue of the New Shares,
Dr. Shaun Furlong will hold 1,507 Ordinary Shares. In
addition, the Deferred Shares have been purchased by the Company
and subsequently cancelled yesterday.
The Company is pleased to confirm
that, in accordance with the terms set out in its articles of
association and pursuant to the terms of a repurchase contract
approved by the shareholders at the Annual General Meeting held on
16 December 2024, all outstanding Deferred Shares have been
purchased by the Company and subsequently cancelled. As such, there
are no longer any Deferred Shares in issue. The purchase and
cancellation of the Deferred Shares have no impact on the Ordinary
Shares in issue.
Details of the purchase of the
Deferred Shares can be found in the notice of the Annual General
Meeting available on the Company's website:
https://www.allergytherapeutics.com/investors/shareholder-services/agm-information.
Total Voting Rights
In accordance with DTR 5.6.1 of the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules ("DTR"), as at
the date of this announcement, the Company has 4,766,439,951
Ordinary Shares in issue. There are no shares held
in treasury. The total number of voting rights in the Company is
therefore 4,766,439,951.
The above figure of
4,766,439,951 may be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the
share capital of the Company under DTR.
- ENDS -
For further information, please
contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science
Specialist Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy
Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Company sells proprietary
and third-party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional
ten countries. For more information, please see www.allergytherapeutics.com.
Notification and public
disclosure of transactions by Director/persons discharging
managerial responsibilities ("PDMR") and persons closely associated
with them ("PCA")
|
1
|
Details of the person
discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Dr. Shaun
Furlong
|
|
2
|
Reason for the
notification
|
|
|
a)
|
Position/status
|
Director of
Allergy Therapeutics Plc.
|
|
b)
|
Initial
notification/Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, UK
emission allowance market participant, auction platform or
auctioneer
|
|
a)
|
Name
|
Allergy
Therapeutics plc
|
|
b)
|
LEI
|
213800PQ7AHK7KGVOE23
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
|
Ordinary
Shares
|
|
b)
|
Nature of
the transaction
|
Issue of
Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price
|
Number of
shares
|
|
£0.539
|
7
|
|
|
|
d)
|
Aggregated
information
· - Aggregated volume
· - Price
|
N/A -
Single transaction
|
|
e)
|
Date of the
transaction
|
21 January
2025
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange, AIM
|
